|
|
|
| home > white papers > The Importance of ADCC in Assessing Clinically Relevant Differences - Sartorius Stedim BioOutsource Ltd |
|
|
 WHITE PAPERS |
|
|
Sartorius Stedim BioOutsource Ltd
|
|
The Importance of ADCC in Assessing Clinically Relevant Differences
|
|
Biosimilars have caused a revolution in the development of biologic
drugs. The model for biosimilars is a combination of speed to market and
low cost; these are fundamental to any biosimilar development project.
The biosimilars pathway to approval is not always without difficulty,
biosimilars are still relatively new, and as each new applicant is
reviewed we are learning more and more about these molecules.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Cargolux pledges millions to support Ukraine
Luxembourg, 4 March 2022 – Cargolux will donate a total of EUR
3.5 million to support humanitarian efforts arising from the war in
Ukraine. This monetary assistance follows the UN’s emergency appeal for
US$1.7 billion to urgently deliver humanitarian support to people in
Ukraine and those who have fled the country in search of safety and
protection.
More info >> |
|
 |
White Papers |
 |
|
Soothing the Logistical Headache of Clinical Trials
Equilibrium Travel Management
As many as 30 per cent of subjects on phase three clinical studies drop out. Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial. It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >> |
|
|
|
